NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.
The ROR1 data are sketchy, and lung toxicity clouds prospects.
One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
The CDK4/6 inhibitor flunks its phase 3 study – a result that should have been foreseen five years ago.
